The safety profile, tolerability, and effective dose range of rofecoxib in the treatment of rheumatoid arthritis. Phase II Rofecoxib Rheumatoid Arthritis Study Group.

[1]  S. Daniels,et al.  Rofecoxib, a specific cyclooxygenase-2 inhibitor, in primary dysmenorrhea: a randomized controlled trial. , 1999, Obstetrics and gynecology.

[2]  D. Riendeau,et al.  Characterization of rofecoxib as a cyclooxygenase‐2 isoform inhibitor and demonstration of analgesia in the dental pain model , 1999, Clinical pharmacology and therapeutics.

[3]  P. Rochon,et al.  Are randomized control trial outcomes influenced by the inclusion of a placebo group?: a systematic review of nonsteroidal antiinflammatory drug trials for arthritis treatment. , 1999, Journal of clinical epidemiology.

[4]  T. Pincus,et al.  Placebo-controlled studies in rheumatoid arthritis: ethical issues , 1999, The Lancet.

[5]  C. Hawkey,et al.  COX-2 inhibitors , 1999, The Lancet.

[6]  J. Vane,et al.  Anti-inflammatory drugs and their mechanism of action , 1998, Inflammation Research.

[7]  Sarfaraz K Niazi,et al.  The effects of non‐steroidal anti‐inflammatory drugs on the disposition of methotrexate in patients with rheumatoid arthritis , 1998, Biopharmaceutics & drug disposition.

[8]  N. Davies,et al.  Clinical Pharmacokinetics of Diclofenac , 1997, Clinical pharmacokinetics.

[9]  J. Chow,et al.  Flexibility of the NSAID binding site in the structure of human cyclooxygenase-2 , 1996, Nature Structural Biology.

[10]  S. Butcher,et al.  Constitutive expression of prostaglandin endoperoxide G/H synthetase (PGHS)-2 but not PGHS-1 in hum an tracheal epithelial cells in vitro. , 1996, Prostaglandins.

[11]  C. Kwoh,et al.  Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. , 1996, Arthritis and rheumatism.

[12]  C. Kwoh,et al.  Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. , 1996, Arthritis and rheumatism.

[13]  F. Berenbaum,et al.  Synergistic Effect of Interleukin-1β and Tumor Necrosis Factor α on PGE2Production by Articular Chondrocytes Does Not Involve PLA2Stimulation , 1996 .

[14]  J. Maclouf,et al.  Involvement of tyrosine kinases in the induction of cyclo-oxygenase-2 in human endothelial cells. , 1995, The Biochemical journal.

[15]  S. Boyce,et al.  Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. , 1995, The Journal of pharmacology and experimental therapeutics.

[16]  J J Anderson,et al.  American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.

[17]  C. Bologna,et al.  Total and free methotrexate pharmacokinetics, with and without piroxicam, in rheumatoid arthritis patients. , 1995, British journal of rheumatology.

[18]  K. Seibert,et al.  Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C. Thiemermann,et al.  Involvement of tyrosine kinase in the induction of cyclo‐oxygenase and nitric oxide synthase by endotoxin in cultured cells , 1994, British journal of pharmacology.

[20]  T. Tracy,et al.  Methotrexate disposition following concomitant administration of ketoprofen, piroxicam and flurbiprofen in patients with rheumatoid arthritis. , 1994, British journal of clinical pharmacology.

[21]  M. Rawlins,et al.  Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs , 1994, The Lancet.

[22]  K. Seibert,et al.  Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[23]  C. Thiemermann,et al.  Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[24]  J J Anderson,et al.  The American college of rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials , 1993 .

[25]  G. Davis,et al.  Interleukin-1 differentially modulates chondrocyte expression of cyclooxygenase-2 and phospholipase A2. , 1993, Experimental cell research.

[26]  David A Jones,et al.  Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. , 1993, The Journal of biological chemistry.

[27]  D. Dewitt,et al.  Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal anti-inflammatory drugs. , 1993, The Journal of biological chemistry.

[28]  J. Richards,et al.  Hormonal regulation of messenger ribonucleic acid encoding a novel isoform of prostaglandin endoperoxide H synthase in rat preovulatory follicles. Induction in vivo and in vitro. , 1992, The Journal of biological chemistry.

[29]  V. Winn,et al.  cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[30]  S. Gabriel,et al.  Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. , 1991, Annals of internal medicine.

[31]  B. Varnum,et al.  TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. , 1991, The Journal of biological chemistry.

[32]  C. Hamilton,et al.  Nonsteroidal Anti‐Inflammatory Drugs: Effects on Kidney Function , 1991, Journal of clinical pharmacology.

[33]  R. Erikson,et al.  Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[34]  W. Bleyer,et al.  Toxicity and serum levels of methotrexate in children with juvenile rheumatoid arthritis. , 1989, Arthritis and rheumatism.

[35]  M. Liang,et al.  The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.

[36]  J. Vane,et al.  Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa , 1980, Nature.

[37]  J. Vane,et al.  An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation , 1976, Nature.

[38]  J. Smith,et al.  Aspirin selectively inhibits prostaglandin production in human platelets. , 1971, Nature: New biology.

[39]  J. Vane,et al.  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. , 1971, Nature: New biology.

[40]  Donald R. Barr,et al.  Using Confidence Intervals to Test Hypotheses , 1969 .

[41]  J. Backman,et al.  Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue: differential elevation of cyclooxygenase 2 in inflammatory joint diseases. , 1998, Arthritis and rheumatism.

[42]  R. Kurumbail,et al.  Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents , 1996, Nature.

[43]  K. Seibert,et al.  Role of inducible cyclooxygenase (COX-2) in inflammation. , 1994, Receptor.

[44]  J. Fries,et al.  Assessing and understanding patient risk. , 1992, Scandinavian journal of rheumatology. Supplement.